ULBP2 and Miyoshi myopathy: Upregulation of NKG2D ligands as “eat me” signals, including MICA/B and ULBP2/3/5, further augment binding of MEDI2228-treated MM cells to the NKG2D receptor on NK cells, resulting in increased NK immune surveillance as well as enhanced daratumumab-induced MM cell killing in in vitro and in vivo preclinical study models.